FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118616237> ?p ?o ?g. }

• W2118616237 endingPage "7" @default.
• W2118616237 startingPage "7" @default.
• W2118616237 abstract "Neoadjuvant chemotherapy is the standard treatment for patients with locally advanced breast cancer and is increasingly considered for patients with operable disease. Recently, as many clinical trials have demonstrated favorable outcomes of anthracycline-taxane based regimen, this approach has been widely used in the neoadjuvant setting.We compared women who received adriamycine and docetaxel (AD) with adriamycin, cyclophosphamide followed by paclitaxel (AC-T) as neoadjuvant chemotherapy. The AD group was scheduled for six cycles of AD (50 mg/m(2) and 75 mg/m(2), respectively) at a 3-week interval. The AC-T group was scheduled for four cycles of adriamycin and cyclophosphamide (50 mg/m(2) and 500 mg/m(2), respectively) followed by four cycles of paclitaxel (175 mg/m(2)) at a 3-week interval.The responses of chemotherapy were equivalent (overall response rate [AD, 75.7% vs. AC-T, 80.9%; P = 0.566], pathologic complete response [pCR] rate [breast and axilla: AD, 10.8% vs. AC-T, 12.8%; P = 1.000; breast only: AD, 18.9% vs. AC-T, 14.9%, P = 0.623], breast conserving surgery rate [P = 0.487], and breast conserving surgery conversion rate [P = 0.562]). The pCR rate in the breast was higher in the human epidermal growth factor receptor 2 (HER2) positive cases (HER2 positive 33.3% vs. negative 10%, P = 0.002). Although nonhematologic toxicities were comparable, hematologic toxicities were more severe in the AD group. Most women in the AD group suffered from grade 3/4 neutropenia (P < 0.001) and neutropenic fever (P < 0.001).Tumor responses were not different in various variables between the two groups. However, AC-T was a more tolerable regimen than AD in patients with breast cancer receiving neoadjuvant chemotherapy." @default.
• W2118616237 created "2016-06-24" @default.
• W2118616237 creator A5038041478 @default.
• W2118616237 creator A5043025424 @default.
• W2118616237 creator A5045341494 @default.
• W2118616237 creator A5046140956 @default.
• W2118616237 creator A5050984590 @default.
• W2118616237 creator A5053029114 @default.
• W2118616237 creator A5060184234 @default.
• W2118616237 creator A5075651504 @default.
• W2118616237 creator A5078521635 @default.
• W2118616237 creator A5078587032 @default.
• W2118616237 creator A5082400192 @default.
• W2118616237 creator A5087248507 @default.
• W2118616237 date "2013-01-01" @default.
• W2118616237 modified "2023-09-25" @default.
• W2118616237 title "Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer" @default.
• W2118616237 cites W1991584640 @default.
• W2118616237 cites W1998580221 @default.
• W2118616237 cites W2001133390 @default.
• W2118616237 cites W2013474338 @default.
• W2118616237 cites W2017098623 @default.
• W2118616237 cites W2019607817 @default.
• W2118616237 cites W2024792080 @default.
• W2118616237 cites W2033878612 @default.
• W2118616237 cites W2048045188 @default.
• W2118616237 cites W2051213632 @default.
• W2118616237 cites W2058085109 @default.
• W2118616237 cites W2083479280 @default.
• W2118616237 cites W2083646500 @default.
• W2118616237 cites W2096620495 @default.
• W2118616237 cites W2103373865 @default.
• W2118616237 cites W2103817501 @default.
• W2118616237 cites W2135753253 @default.
• W2118616237 cites W2138902655 @default.
• W2118616237 cites W2140654333 @default.
• W2118616237 cites W2153158488 @default.
• W2118616237 cites W2159829953 @default.
• W2118616237 cites W2162760540 @default.
• W2118616237 cites W2163403096 @default.
• W2118616237 cites W2171958606 @default.
• W2118616237 doi "https://doi.org/10.4174/jkss.2013.85.1.7" @default.
• W2118616237 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3699689" @default.
• W2118616237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23833754" @default.
• W2118616237 hasPublicationYear "2013" @default.
• W2118616237 type Work @default.
• W2118616237 sameAs 2118616237 @default.
• W2118616237 citedByCount "5" @default.
• W2118616237 countsByYear W21186162372016 @default.
• W2118616237 countsByYear W21186162372018 @default.
• W2118616237 countsByYear W21186162372021 @default.
• W2118616237 countsByYear W21186162372023 @default.
• W2118616237 crossrefType "journal-article" @default.
• W2118616237 hasAuthorship W2118616237A5038041478 @default.
• W2118616237 hasAuthorship W2118616237A5043025424 @default.
• W2118616237 hasAuthorship W2118616237A5045341494 @default.
• W2118616237 hasAuthorship W2118616237A5046140956 @default.
• W2118616237 hasAuthorship W2118616237A5050984590 @default.
• W2118616237 hasAuthorship W2118616237A5053029114 @default.
• W2118616237 hasAuthorship W2118616237A5060184234 @default.
• W2118616237 hasAuthorship W2118616237A5075651504 @default.
• W2118616237 hasAuthorship W2118616237A5078521635 @default.
• W2118616237 hasAuthorship W2118616237A5078587032 @default.
• W2118616237 hasAuthorship W2118616237A5082400192 @default.
• W2118616237 hasAuthorship W2118616237A5087248507 @default.
• W2118616237 hasBestOaLocation W21186162371 @default.
• W2118616237 hasConcept C121608353 @default.
• W2118616237 hasConcept C126322002 @default.
• W2118616237 hasConcept C143998085 @default.
• W2118616237 hasConcept C2776694085 @default.
• W2118616237 hasConcept C2776755627 @default.
• W2118616237 hasConcept C2776802502 @default.
• W2118616237 hasConcept C2777292972 @default.
• W2118616237 hasConcept C2777511904 @default.
• W2118616237 hasConcept C2778292576 @default.
• W2118616237 hasConcept C2781190966 @default.
• W2118616237 hasConcept C2781413609 @default.
• W2118616237 hasConcept C530470458 @default.
• W2118616237 hasConcept C71924100 @default.
• W2118616237 hasConcept C90924648 @default.
• W2118616237 hasConceptScore W2118616237C121608353 @default.
• W2118616237 hasConceptScore W2118616237C126322002 @default.
• W2118616237 hasConceptScore W2118616237C143998085 @default.
• W2118616237 hasConceptScore W2118616237C2776694085 @default.
• W2118616237 hasConceptScore W2118616237C2776755627 @default.
• W2118616237 hasConceptScore W2118616237C2776802502 @default.
• W2118616237 hasConceptScore W2118616237C2777292972 @default.
• W2118616237 hasConceptScore W2118616237C2777511904 @default.
• W2118616237 hasConceptScore W2118616237C2778292576 @default.
• W2118616237 hasConceptScore W2118616237C2781190966 @default.
• W2118616237 hasConceptScore W2118616237C2781413609 @default.
• W2118616237 hasConceptScore W2118616237C530470458 @default.
• W2118616237 hasConceptScore W2118616237C71924100 @default.
• W2118616237 hasConceptScore W2118616237C90924648 @default.
• W2118616237 hasIssue "1" @default.
• W2118616237 hasLocation W21186162371 @default.
• W2118616237 hasLocation W21186162372 @default.
• W2118616237 hasLocation W21186162373 @default.

• next